FDA approves Hepcludex for chronic hepatitis D

The FDA approved Hepcludex injection for the treatment of chronic hepatitis D infection in adults without cirrhosis or with compensated cirrhosis, according to a press release. Hepcludex (bulevirtide-gmod, Gilead Sciences) is the first FDA-approved treatment for the condition.

venerdì 22 maggio 2026 New tab

May 22, 2026

1 min read

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

FDA approves Hepcludex for chronic hepatitis D

FDA approves Hepcludex for chronic hepatitis D

Other newsrooms on this story

Related reading

FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the…

FDA clears Gilead's hepatitis D drug, four years after prior rejection

FDA OKs First Treatment for Chronic Hepatitis D Infection

After prior FDA manufacturing snub, Gilead's hepatitis D med Hepcludex nabs US…

All Specialties News

Liver diagnostic test gains FDA premarket approval for compensated cirrhosis

Other newsrooms on this story

Related reading

FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the…

FDA clears Gilead's hepatitis D drug, four years after prior rejection

FDA OKs First Treatment for Chronic Hepatitis D Infection

After prior FDA manufacturing snub, Gilead's hepatitis D med Hepcludex nabs US…

All Specialties News

Liver diagnostic test gains FDA premarket approval for compensated cirrhosis